Colorectal Neoplasms Clinical Trials in Houston, Texas
10 studies are recruiting for colorectal neoplasms in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.
Search these by distance from you
Studies now recruiting
-
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
The purpose of this study is to find out whether the study drug, Sofetabart Mipitecan (LY4170156), is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in three parts - phase Ia (dose-escalation, dose-optimization), phase Ib (dose-expansion), and phase…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- The University of Texas - MD Anderson Cancer Center, Houston, Texas
- Locations
- 24 in total
- Run by
- Eli Lilly and Company
-
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
The main purpose of this study is to evaluate safety, tolerability, and efficacy of LY4257496 alone and as part of relevant standard of care (SOC) combination therapy in participants with Gastrin-releasing Peptide Receptor (GRPR)-positive advanced cancer, including but not limited to breast, colore…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- MD Anderson Cancer Center, Houston, Texas
- Locations
- 33 in total
- Run by
- Eli Lilly and Company
-
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, side effects, and efficacy of LY4337713.…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Baylor College of Medicine, Houston, Texas
- Locations
- 30 in total
- Run by
- Eli Lilly and Company
-
PRE-ISPY Phase I/II Oncology Platform Program
PRE-ISPY Phase I/II (I-SPY-P1) is an open-label, multisite platform study with multiple ongoing drug regimen arms added by protocol amendment which is designed to evaluate single agents or combinations in locally advanced, incurable, or metastatic solid tumors and/or oligometastatic malignancy and/…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- The University of Texas MD Anderson Cancer Center, Houston, Texas
- Locations
- 10 in total
- Run by
- QuantumLeap Healthcare Collaborative
-
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxaliplatin (mFOLFOX6) or 5-fluorouracil, leucovorin calcium (folin…
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- MD Anderson Cancer Center, Houston, Texas
- Locations
- 239 in total
- Run by
- Janssen Research & Development, LLC
-
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovo…
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- MD Anderson Cancer Center, Houston, Texas
- Locations
- 251 in total
- Run by
- Janssen Research & Development, LLC
-
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
The purpose of this study is to learn more about a new medicine called PF-08634404, and how well it works in people with cancer of the colon or rectum (CRC)). The goal is to understand if the new study medicine, combined with chemotherapy that is approved for colorectal cancer, can help people whos…
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- Oncology Consultants P.A., Houston, Texas
- Locations
- 308 in total
- Run by
- Pfizer
-
A Study of DM002 in Patients With Advanced Solid Tumors
The goal of study: The study has two parts: Part 1 Dose Escalation and Part 2 Dose Expansion. In Part 1, a few participants will receive the lowest dose of study drug. The study team will make sure it is safe and tolerated before enrolling new participants at a higher dose of study drug. There will…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- The University of Texas, MD Anderson Cancer Center, Houston, Texas
- Locations
- 7 in total
- Run by
- Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
-
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participants take this combination of drugs. A side effect is anythin…
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- The University of Texas MD Anderson Cancer Center, Houston, Texas
- Locations
- 366 in total
- Run by
- Seagen, a wholly owned subsidiary of Pfizer
-
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts …
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- The University of Texas MD Anderson Cancer Center, Houston, Texas
- Locations
- 48 in total
- Run by
- Seagen, a wholly owned subsidiary of Pfizer
How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.
What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.
Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.